| Bone mineral density | In young women, no clear difference in bone density versus placebo was found over 10 months.No convincing between-group difference in bone mineral density was found. | 1/4 Very lowEstimate precision: Very serious limitation: 28 women divided into cells of 5–10; no precise between-group estimate of change or interval to rule out a meaningful effect. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: single blinding; allocation concealment and blinding of the bone-density assessor are unclear; objective measurement reduces reporting-distortion risk. | 11 trialEffects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes ↗ | 28 female students aged 18–25, including 17 athletes and 11 sedentary students | - Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes ↗
|
|---|
| Total WOMAC score | After two weeks, the total WOMAC score for knee pain, stiffness and function fell by 13.73 points more than with placebo.Difference in WOMAC changes on day 14: −13.73 points (95% CI −19.28…−8.19) between calcium fructoborate and placebo; on day 7: −5.30 (95% CI −10.84…0.24), p=0.061. | 2/4 LowEstimate precision: Small sample; for some outcomes, between-group effect size and CI are absent from the available package. Consistency of findings: One relevant trial per outcome; reproducibility not assessed. Applicability to the specified group: Limited to the specified population, form, dose and duration; do not transfer to other groups or products. Possible publication bias: Undetermined with a single study. Study methods: Limited assessment: a full independent RoB 2 was not performed; some allocation, selective reporting and attrition methods are unknown. Commercial ties and retrospective registration were disclosed for the knee trial. | 11 trialShort-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗ | 60 adults with self-reported knee discomfort | - Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗
|
|---|
| Total McGill Pain Questionnaire score | After two weeks, the McGill pain score fell by 8.9 points more than with placebo.Difference in changes on day 14: −8.9 points, 95% CI −12.32…−5.48; on day 7: −5.8 points, p=0.0009. | 2/4 LowEstimate precision: Serious limitation: 60 participants; the confidence interval excludes zero, but the threshold for meaningful benefit and its persistence in this group are unknown. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: commercial and patent interests, retrospective registration, unclear allocation concealment and subjective assessment. | 11 trialShort-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗ | 60 adults with self-reported knee discomfort | - Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗
|
|---|
| Self-rated everyday physical function | In a supplementary analysis, participants reported better everyday function from day 30 compared with placebo.Both active regimens differed from placebo in self-rated everyday function from day 30. The published abstract provides no numerical between-group difference or confidence interval. | 1/4 Very lowEstimate precision: Serious limitation: no usable between-group contrast or confidence interval; magnitude and clinical importance are unknown. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns self-rated everyday activity in the adults studied, not objective mobility or the 14-day trial result. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Very serious limitation: a sponsor-linked supplementary exploratory analysis of many scales, items, regimens and time points is not a prespecified confirmatory result. | 11 trialImpact of Calcium Fructoborate on WOMAC and McGill Subscales and Individual WOMAC Questions: Post-Hoc Analyses of Data from a Previously Published 90-Day Randomized Clinical Trial ↗ | 120 adults with self-reported knee discomfort, 40 in each of three groups | - Impact of Calcium Fructoborate on WOMAC and McGill Subscales and Individual WOMAC Questions: Post-Hoc Analyses of Data from a Previously Published 90-Day Randomized Clinical Trial ↗
|
|---|
| Total plasma testosterone | No additional change in total testosterone versus placebo was found.Total testosterone increased in both groups; no additional boron effect was found. | 1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group. In Naghii 2011, eight men received placebo then boron without a parallel control; this is neither an independent replication nor a contradiction of this comparison. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and concealment unclear; baseline training, calories and carbohydrates differed. | 11 trialThe effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗ | 19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week | - The effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗
|
|---|
| Free plasma testosterone | No difference in free testosterone versus placebo was found.No significant additional effect on free testosterone was found. | 1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group. In Naghii 2011, eight men received placebo then boron without a parallel control; this is neither an independent replication nor a contradiction of this comparison. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training and diet differed. | 11 trialThe effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗ | 19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week | - The effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗
|
|---|
| Squat and bench-press strength | No additional gain in squat and bench-press strength versus placebo was found.Both exercises improved over time; no additional boron effect was found. Complete data: squat 9 versus 6, bench press 9 versus 9. | 1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group, so between-trial consistency cannot be assessed. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training differed, and complete-case analysis after injuries further limits strength assessment, especially the squat. | 11 trialThe effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗ | 19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week | - The effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗
|
|---|
| Fat-free body mass | No additional gain in fat-free mass versus placebo was found.Fat-free mass increased during training without a significant additional boron effect. | 1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group, so between-trial consistency cannot be assessed. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training and diet differed, potentially affecting fat-free mass change. | 11 trialThe effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗ | 19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week | - The effect of boron supplementation on lean body mass, plasma testosterone levels, and strength in male bodybuilders ↗
|
|---|
| Menstrual pain intensity | In the second cycle, pain scores were 4.35 versus 5.87 points; the between-group difference in changes was not statistically significant.Second cycle: 4.35 versus 5.87 out of 10; baseline: 5.90 versus 6.44. For the comparison of changes, p=0.074. | 1/4 Very lowEstimate precision: Very serious limitation: one small trial without a confidence interval for the group-by-time interaction or adjusted change; the longitudinal comparison does not distinguish an effect from no effect, and the final difference includes baseline imbalance. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: symptom-severity blocks and triple blinding strengthen the design, but allocation concealment is not described; 1 and 4 women withdrew without an analysis of all randomized women; ratings are subjective and multiple analyses were performed. | 11 trialEffects of boron supplementation on the severity and duration of pain in primary dysmenorrhea ↗ | Female students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed | - Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea ↗
|
|---|
| Duration of menstrual pain | In the second cycle, pain lasted an average of 2.74 hours versus 4.08 hours with placebo.Second cycle: 2.74 versus 4.08 hours; baseline: 4.15 versus 4.46 hours; comparison of changes p=0.020. | 2/4 LowEstimate precision: Serious limitation: 113 analyzed; no confidence interval for the group-by-time interaction or adjusted effect; unadjusted results do not establish the precise magnitude. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: symptom-severity blocks and triple blinding strengthen the design, but allocation concealment is not described; 1 and 4 women withdrew without an analysis of all randomized women; ratings are subjective and multiple analyses were performed. | 11 trialEffects of boron supplementation on the severity and duration of pain in primary dysmenorrhea ↗ | Female students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed | - Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea ↗
|
|---|